(Reuters) - Embattled Valeant Pharmaceuticals International Inc VRX.NVRX.TO said on Wednesday it has added a representative from shareholder Pershing Square Capital Management to its board of directors as well as two other new directors.
Pershing Square, run by activist investor Bill Ackman, bought a stake in Valeant last year when the drugmaker’s shares were on the rise. They have fallen 68 percent since.
Valeant said later on Wednesday it had jointly ended litigation with R&O Pharmacy with both sides asking the court to dismiss case. R&O was not immediately available for comment on the settlement.
While Valeant did not disclose the terms of the settlement, it said the resolution included a payment by R&O to Valeant. [nPn3vWq4v]
R&O sued Valeant in federal court in California on Oct. 6, after receiving a demand letter from Valeant for more than $69 million, money that R&O said it did not owe. [nL1N12P0OC]
Valeant later countersued R&O, according to the Wall Street Journal.
Last fall, the company became the target of two U.S. state investigations into its drug pricing practices, and its relationship with Philidor RX Services, a pharmacy selling its dermatology products, came under scrutiny and was dissolved. [nL3N12U450]
During the last two weeks, the company delayed its annual financial filing with regulators, postponed a preliminary earnings announcement, and said it would restate financials. Chief Executive Officer Michael Pearson returned from a two-month medical leave and a top dermatology executive left. It also disclosed an investigation by the U.S. Securities and Exchange Commission.
Stephen Fraidin, a veteran Wall Street lawyer who is vice chairman at Pershing Square, joined the board, Valeant said. He previously worked at the Kirkland & Ellis law firm before joining Pershing last year.
Fred Eshelman, a drug executive who founded Furiex Pharmaceuticals Inc, and Thomas Ross, an academic who is a fellow at Duke University and president emeritus of the University of North Carolina, also joined the board.
Anders Lonner, former CEO of Swedish specialty drug company Meda AB MEDAa.ST, stepped down from the board, Valeant said. The board now has 14 members.
Wells Fargo analyst David Maris, who has an “underperform” rating on the stock, said in a research note that Pershing Square had proposed Eshelman for the board at Allergan during its and Valeant’s failed hostile bid for the company.
Maris said investors will likely have reservations about Ross as well, given his ties to Duke University, to which CEO Pearson has donated $45 million.
Valeant plans to report preliminary fourth-quarter earnings and hold a conference call on March 15.
On Tuesday, Ackman said the company will reveal “messy” fourth- and first-quarter results, and said Valeant needed to stabilize soon. If not, new management will be brought in or the company will be sold, he said.
Valeant’s board set up a committee last year to look into the relationship between Valeant and Philidor. As a result of that ongoing investigation, it is restating financials. The committee is advised by Mark Filip, a partner at Kirkland & Ellis.
On Wednesday, its shares rose 6.6 percent to $67.20.
Reporting by Caroline Humer in New York and Ankur Banerjee in Bengaluru; Editing by Ted Kerr and Alan Crosby
Our Standards: The Thomson Reuters Trust Principles.